Clinical Trial: Mechanism of Action of TRAVATAN 0.004% in Subjects with Glaucoma or Ocular Hypertension


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Mechanism of Action of TRAVATAN 0.004% in Subjects with Glaucoma or Ocular Hypertension

This study is currently recruiting patients.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research

Purpose

The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).

Condition	Treatment or Intervention	Phase
Glaucoma Ocular Hypertension	Drug: Travoprost	Phase IV

MedlinePlus related topics: Eye Diseases; Glaucoma

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects with Glaucoma or Ocular Hypertension

Further Study Details:

Study start: April 2003

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both

Criteria

Subjects 18 years of age or older
of either sex
of any race
diagnosed with ocular hypertension or open angle glaucoma

Location and Contact Information

Alcon Call Center Alcon Representative (888)451-3937 (EYES) alconlabs.com

Nebraska
Alcon Call Center, Call for Details, Nebraska, United States; Recruiting

Alcon Representative 888-451-3937

More Information

Study ID Numbers: C-01-55
Record last reviewed: May 2003
Record first received: May 28, 2003
ClinicalTrials.gov Identifier: NCT00061503
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services